New treatments for Non-Hodgkin lymphoma linked to Epstein-Barr virus
Official title: Therapy for Non-Hodgkin lympoma
Funded at Univ of North Carolina Chapel Hill · NIH-11020542 · Data updated 2026-11-12
This study is looking at how the Epstein-Barr virus might be linked to certain types of Non-Hodgkin lymphoma in people with HIV, with the goal of finding new ways to treat these tough-to-treat cancers and help patients feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $435,506 |
| NIH project number | 1R01CA291437-01A1 |
| Project ID | NIH-11020542 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Non-Hodgkin lymphoma, especially those who are also HIV-positive.
✕Less likely to help
Patients with Non-Hodgkin lymphoma who are not infected with HIV may not benefit directly from this research.
What this research studies
This research investigates the connection between Epstein-Barr virus (EBV) and various types of Non-Hodgkin lymphoma (NHL), particularly in patients with HIV. The team aims to understand how EBV contributes to the development and persistence of these aggressive lymphomas, which are often resistant to current treatments. By exploring the biology of these cancers, the researchers hope to identify new therapeutic strategies that could improve outcomes for affected patients. The study will involve analyzing tumor samples and patient data to uncover potential targets for innovative therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with Non-Hodgkin lymphoma, particularly those who are HIV-positive.
How similar studies have gone: Previous research has shown promising results in targeting EBV-associated malignancies, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Damania, Blossom a — Univ of North Carolina Chapel Hill
- Study coordinator: Damania, Blossom a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.